^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RNA-NP vaccine

    i
    Other names: RNA-NP vaccine, Autologous total tumor mRNA loaded DOTAP liposome vaccine, mRNA-NP (nanoparticle) vaccine
    Associations

    News

    Trials
    Company:
    University of Florida
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    5ms
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Florida | Suspended --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    RNA-NP vaccine
    8ms
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Suspended, University of Florida | Recruiting --> Suspended
    Trial suspension
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    RNA-NP vaccine
    12ms
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Recruiting, University of Florida | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    RNA-NP vaccine
    12ms
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, University of Florida
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    RNA-NP vaccine
    over1year
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, University of Florida | Trial completion date: Jul 2027 --> Sep 2026 | Trial primary completion date: Jul 2025 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    RNA-NP vaccine
    almost2years
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, University of Florida | Initiation date: Jan 2023 --> Jun 2023
    Trial initiation date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    RNA-NP vaccine
    2years
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, University of Florida | Initiation date: Oct 2022 --> Jan 2023
    Trial initiation date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    RNA-NP vaccine
    over2years
    Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, University of Florida | Initiation date: May 2022 --> Oct 2022
    Trial initiation date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    RNA-NP vaccine